Henry Schein, Inc. $HSIC Shares Purchased by Snyder Capital Management L P

Snyder Capital Management L P boosted its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 18.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,334,364 shares of the company’s stock after purchasing an additional 209,123 shares during the period. Henry Schein comprises approximately 1.7% of Snyder Capital Management L P’s investment portfolio, making the stock its 18th biggest holding. Snyder Capital Management L P owned approximately 1.13% of Henry Schein worth $88,562,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP lifted its holdings in shares of Henry Schein by 6.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,596,168 shares of the company’s stock valued at $172,304,000 after buying an additional 159,087 shares during the period. Cresset Asset Management LLC lifted its holdings in Henry Schein by 1.6% in the third quarter. Cresset Asset Management LLC now owns 198,194 shares of the company’s stock valued at $13,154,000 after acquiring an additional 3,165 shares during the period. Huntington National Bank boosted its position in Henry Schein by 20.4% in the 3rd quarter. Huntington National Bank now owns 1,487 shares of the company’s stock worth $99,000 after purchasing an additional 252 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of Henry Schein during the 3rd quarter worth approximately $165,000. Finally, Artisan Partners Limited Partnership grew its stake in shares of Henry Schein by 5.7% during the 3rd quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after purchasing an additional 370,837 shares during the period. 96.62% of the stock is owned by institutional investors and hedge funds.

Henry Schein Stock Performance

Shares of NASDAQ:HSIC opened at $80.58 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76. The business’s 50 day moving average price is $78.09 and its 200-day moving average price is $72.44. The firm has a market capitalization of $9.24 billion, a PE ratio of 24.64, a P/E/G ratio of 2.37 and a beta of 0.88. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $89.29.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same period in the prior year, the company earned $1.19 EPS. The firm’s revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities research analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HSIC. Mizuho increased their price target on shares of Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. JPMorgan Chase & Co. raised their target price on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Leerink Partners lifted their price target on Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a research note on Tuesday, February 24th. Wells Fargo & Company increased their price target on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Finally, Evercore raised their price objective on Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $85.58.

Insiders Place Their Bets

In related news, CEO Stanley M. Bergman sold 43,812 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the completion of the sale, the chief executive officer owned 383,803 shares of the company’s stock, valued at approximately $31,207,021.93. This represents a 10.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 92,943 shares of company stock worth $7,544,505 in the last quarter. Insiders own 1.08% of the company’s stock.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.